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ABSTRACT 
 
Several oncogenes and tumor-suppressor genes are involved either as early or 
late event in thyroid gland carcinogenesis. Human FHIT (fragile histidine triad) gene 
is highly conserved gene whose loss of function may be important in the development 
and/or progression of various types of cancer. We undertook this study to analyze 
FHIT and p53 gene status in different benignant and malignant thyroid tumors. Status 
of these genes as well as intensity of apoptosis were analyzed in tumor tissues by 
molecular genetic methods, immunohistochemistry, and FACS-scan analysis. The 
majority of the malignant thyroid cancers displayed aberrant expression of FHIT 
gene, concominant with p53 gene inactivation. This is followed by low rate of 
apoptosis which may be important in the development and/or progression of thyroid 
cancer. We found higher incidence of p53 mutation and aberrant processing of FHIT 
mRNA in malignant tumors (papillary, follicular, medullary and anaplastic 
carcinomas) and in those tumors with distant metastasis. The growth of p53-/FHIT- 
follicular carcinoma of human origin was much faster in nude mice than p53+/FHIT+ 
follicular carcinoma, and mice had shorter survival rate. Our results show a 
correlation between aberrant FHIT and p53 expression, low rate of apoptosis, and 
malignancy. Concomitant aberration of FHIT gene and p53 could be responsible for 
development of highly malignant types of thyroid cancer and may be considered as a 
prognostic marker for these tumors.  
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INTRODUCTION 
 
Thyroid gland tumors exhibit a broad spectrum of neoplastic pathology, 
ranging from benign colloid adenomas to fatal anaplastic carcinomas [1]. Several 
oncogenes (ras, ret, trk) and tumor-suppressor genes (p53, Rb, p16/CDKN2, p21waf1) 
have been associated with this kind of tumors. Ras oncogene activation is an early 
event and appears to be involved in the genesis of follicular adenoma and carcinoma 
[2]. Three other genetic and/or epigenetic alterations play a role in PTC pathogenesis: 
activating mutation of ras genes, c-met overexpression and downregulation of E-
cadherin in papillary carcinoma. Recently, another major player in papillary 
carcinoma etiopathogenesis has been reported: the BRAF gene. Papillary carcinoma is 
one of the human cancers displaying the highest prevalence of BRAF mutations, 
which occur almost always in the same hot spot (V600E). The finding of a high 
prevalence of BRAF mutations, together with the involvement of ras mutations and 
ret/PTC rearrangements in the majority of papillary carcinomas, points to the crucial 
role played by alterations at the ret/ras/BRAF/MAPK signal transduction pathway in 
the pathogenesis of papillary carcinoma [3]. Generally, mechanisms governing the 
transformation of normal thyroid cells into carcinoma are not well understood. 
Thyroid epithelium is the second most common tissue type (after blood) where fusion 
gene products are critical for the early development of cancer [4]. The ret gene is 
frequently inverted or translocated to form the fusion genes ret/PTCs [5] but those 
genes alone are insufficient to cause cancer and require the simultaneous or 
accumulated activation of multiple gene products to progress from early differentiated 
stages to undifferentiated stages of malignancy. 
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The FHIT gene, located in 3p14.2 is very often inactivated in various types of 
cancer [6-8]. The mechanisms of FHIT inactivations are bialelic deletions, loss of 
heterozygosity, aberrant methylation, while point mutations are rare [9-11]. FHIT is 
encoded at FRA3B, the most frequent fragile site in human genome and FHIT loss is 
a frequent event in carcinogenesis [8]. 
Loss of FHIT protein expression and abnormal FHIT transcripts, including 
deletions of exons and insertions, are found in a high percent in lung and breast 
cancers [6,12-14] as well as in head and neck cancers [15]. FHIT is a putative tumor 
suppressor and belongs to the histidine triad superfamily of nucleotide-binding 
proteins. Re-expression of FHIT in cancer cell lines with FHIT-deletions suppressed 
their ability to form tumors in mice [16]. Analysis of preneoplastic and neoplastic 
lesions from the lungs of smokers has indicated that events that lead to lack of 
expression of FHIT are the earliest and the most frequent identified genetic changes in 
lung cancers [6]. 
Several studies indicate the aberration of FHIT gene in thyroid cancer. McIver 
et al. [17] found abnormal RNA processing as a common event in thyroid neoplasms. 
Zou et al. [2] described defective FHIT gene in both benign and malignant thyroid 
tumors, suggesting that the inactivation of this tumor suppressor gene is likely to be 
an early event in the pathogenesis of some forms of thyroid neoplasms. 
Gene p53 is another important gene in thyroid cancer progression. Some data 
suggest that p53 mutations are involved in thyroid carcinogenesis and may play an 
important role in the malignant transformation of thyroid cells as well as thyroid 
tumor progression [18]. Alteration in p53 contribute to development of metastatic 
forms of follicular thyroid carcinoma [19]. 
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The aim of this study was to determine the prognostic significance of FHIT 
and p53 genes alterations in thyroid lesions. To investigate whether the FHIT gene is 
important in thyroid tumor carcinogenesis, we screened the FHIT gene for alterations 
in different thyroid benign and malignant lesions. We also investigated mechanisms 
of FHIT gene inactivation and correlated our results with status of p53, and intensity 
of apoptosis.  
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Materials and methods  
 
Patients and tissue specimens  
Normal thyroid tissue, benign thyroid lesions (adenomatous goiter, follicular 
adenoma, thyroiditis, Graves disease and Hutrle adenoma) and malignant tumors 
(papillary, follicular, medullary and anaplastic carcinoma) were obtained from 
Department of Head and Neck Surgery, Hospital Ana Costa and Santa Casa da 
Misericordia and School of Medicine, Metropolitan University Santos, Brasil, from 
Clinical Hospital "Sestre milosrdnice", Zagreb, from General Hospital Slavonski 
Brod, from Clinical Hospital Center Zagreb, Department of Otorhinolaryngology and 
Head and Neck Surgery "Salata", Zagreb and from Croatian Tumor Bank [20]. All 
specimens were obtained during routine surgery. The tissue were snap frozen in liquid 
nitrogen shortly after surgical removal and stored at –800C. A part of each frozen 
tumor sample was also embedded in paraffin. Sections of each paraffin block were 
stained with hematoxylin and eosin to confirm the exact tissue analyzed. The study 
included 62 men and 213 women with age range between 18 and 72 years (mean age, 
48.8 years). 
 
Immunohistochemical analysis 
Immunohistochemical detection of FHIT was done using the anti-FHIT rabbit 
polyclonal antibody (1:80 dilution; Zymed, USA). The endogenous  peroxidase 
activity was quenched by methanol containing 3% hydrogen peroxide (Sigma, 
Taufkirchen, Germany). Nonspecific binding was blocked by applying normal rabbit 
serum in a humidity chamber at a dilution of 1:10 for 30 min. Primary rabbit anti-
FHIT antibody was applied overnight at 40C. The secondary antibody (goat to mouse 
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immunoglobulins, DAKO, Denmark) was applied for 1 hour at room temperature. 
Peroxidase-antiperoxidase (PAP rabbit, DAKO) conjugate diluted 1:100 in 
phosphate-buffered saline (PBS) was applied for 45 min at room temperature. The 
slides were stained with diaminobenzidine tetrahydrochloride (DAB, Sigma) and then 
counterstained with hematoxylin.  
Control staining was performed by omitting the primary antibody. As positive 
control in immunohistochemical studies, we used paraffin slides of the lung cancer 
positive for FHIT protein. 
The localization and level of specific immunostaining for each slide was 
evaluated in the whole tumor area. The relative level of specific immunostaining and 
its localization were judged. The relative intensity of cell immunostaining was 
evaluated semiquantitatively, so that no staining was denoted (0), weak staining was 
denoted (1), moderate (2), and strong (3). Each sample was assessed independently by 
two observers. There was a 95 % initial agreement between them. 
  
Loss of heterozigosity analysis 
Tumor DNAs were extracted from frozen tumor tissue obtained during routine 
surgery of patients with thyroid gland lesions and stored at –80°C. All tumor 
specimens were examined by routine hematoxylin-eosin staining to determine the 
proportion of tumor cells in the sample (it had to be more than 80%). Control normal 
DNA was extracted from peripheral blood of patients. Frozen-tissue and blood DNA 
extraction was performed using proteinase K digestion and phenol chloroform 
extraction.  
To analyze LOH at the FHIT gene locus, we used D3S1300 dinucleotide 
repeat and D3S4103 trinucleotide repeat and VNTR analysis as it was described 
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previously [15]. LOH at the p53 gene locus was also anlyzed by VNTR analysis and 
highly informative exogenic (CA)n repeat as it was previously described [21]. 
LOH was defined by visible change in allele:allele ratio in tumors compared 
with matching normal tissue. Allelic deletion of FHIT was judged by a positive LOH 
at any of the two sites. 
 
p53 mutations analysis 
p53 gene mutations analysis was performed by SSCP analysis of all p53 gene 
exons. Mutations were detected by direct sequencing of the relevant genomic DNA 
fragments with aberrant profile in SSCP analysis using CircumVent TM Termal 
Cycle dideoxy DNA sequencing kit (New England Biolabs) according to the 
manufacturer's instructions. Mutations were additionally confirmed using 
fluorescence-based dideoxy sequencing on Applied Byosistems Model 373A 
automated sequencer. 
 
RNA extraction and reverse transcription  
Total RNA from tissues was extracted using RNAzolTMB reagent (Biogenesis, 
Poole, UK) according to manufacturer's protocol. Recovered RNA was assayed by a 
260/280 nm ratio. 
The RT-PCR reaction was performed in a total volume of 40 µl. Total RNA 
(10 µg), 0.4 mM oligo (dT)18 (New England Biolabs), and QH2O up to 24 µl were 
prepared. After incubation for 10 min at 70˚C the mixture was quickly cooled on ice 
and 16 µl of RT reaction mixture containing 8 µl of 5 x First strand buffer 
(Invitrogen)(250 mM Tris HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 4 µl of 0.1M 
DTT (Invitrogen), 2 µl 10 mM deoxynucleotide mixture (dATP, dTTP, dCTP and 
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dGTP, 10 mM each)(Roche), 2 µl of Rnase inhibitor (40 U/µl)(Roche) was added. 
The reaction proceeded in GeneAmp 2400 (Applied Biosystems) at  45˚C for 2 min. 
Followed by the addition of 400 units of SuperScriptTMRnaseH- reverse transcriptase 
(200 U/µl)(Invitrogen), the reaction was incubated at 45˚C for 60 min. The reaction 
was inactivated at 70˚C for 15 min and at 94˚C for 3 min. The cDNA was used as a 
template in the following PCR reactions. 
 
FHIT gene expression analysis 
The FHIT gene expression analysis was performed by nested RT-PCR method as it 
was described previously [15]. Half of microliter of cDNA was used for PCR 
amplifications with primers 5U2 and 3D2 from FHIT exons 1 and 10, respectively. 
Amplification was carried out in 25 µl volume. The PCR mixture consisted of 0.5 µl 
of cDNA, 2.5 µl of 10xPCR buffer II (Applied Biosystems), 1.5 mM of MgCl2, 50 
µM of each dNTP, 5 pmol of each specific primer, and 1U of Taq DNA polymerase 
(Applied Biosystems). The PCR consisted of an initial denaturation step at 950C for 5 
min, followed by 45 cycles of 30 sec at 960C, 30 sec at 560C, and 45 sec at 720C. 
Final extension lasted 10 min. Two microliters of first PCR products were used for 
nested PCR amplifications with primers 5U1 and 3D1 from FHIT exons 3 and 10, 
respectively. The PCR products were resolved by agarose gel electrophoresis (1.5% 
agarose stained with 0.5 µg/ml ethidium bromide). RT-PCR products were directly 
sequenced after isolation of bands from low melting agarose and purification on 
columns. The sequencing of aberrant PCR products was performed as described 
previously [22]. 
 
Analysis of apoptosis  
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FACScan analysis of apoptosis was performed according to the procedure of 
Sard et al. [23]. Two million cells per sample were fixed with 2% paraformaldehyde 
in PBS, washed twice with TBS (50 mM Tris-HCl in saline solution), and 
permeabilized for 1 min with ice cold acetone. Staining was performed by incubating 
cells for 1 hr at 370 C in 25 µl of TUNEL reaction mixture – In Situ Cell Death 
Detection Kit (Roche, Germany). Samples were analyzed by FACScan (Becton 
Dickinson, Erembodegem-Aalst, Belgium). 
 
Cultivation of primary carcinoma cells 
Surgical specimens were collected into sterile vessels containing RPMI 1640 
medium with 10% heat inactivated fetal calf serum and 5% human serum. Informed 
consent was obtained from all patients from whom surgical specimens were obtained. 
Tumor tissue, without necrosis, was mechanically disrupted, placed into medium, cut 
into small pieces and pressed through a nylon sieve. Cells were introduced into T-75 
flasks with RPMI 1640 medium supplemented with 9% fetal calf serum (FCS), 1% 
calf serum and 5% human serum, 2 mM L-glutamine and 20 mM HEPES. Tumor cell 
cultures were maintained as monolayers. The initial inoculum was about 1.8 x 105 
cells per T-75 flask, and cells were cultivated in RPMI 1640 medium supplemented 
with transferrin (5 µg/ml), selenic acid (5 ng/ml) and HEPES (20 mM). Cells were 
store frozen (2 x 106 cells/ampule) in liquid nitrogen with 70% medium, 20% FCS 
and 10% DMSO. Two primary cultures of follicular carcinoma were established. One 
cell line was p53-/FHIT- and another was p53+/FHIT+. Both cell lines were inoculated 
into nude mice. 
 
Tumorigenicity in nude mice 
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Follicular thyroid carcinoma cells from primary culture were inoculated s.c. 
into dorsal region of 4 seven week old nude mice. The tumor volume for each mouse 
was determined by measuring in two directions and calculated as tumor volume = 
length x (width)2/2. 
 
Statistical analysis  
Descriptive statistics are presented as mean ± standard deviation. For ordinary 
data, descriptive statistics are presented with median and percentiles or as 
percentages. The table was analyzed with Fisher’s exact test. Box-Whisker plots were 
generated in the basic module of the program Statistica. The correlation between 
apoptosis and FHIT gene status was analyzed with the Wilcoxon rank-sum test. 
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Results 
 
FHIT protein expression in thyroid lesions 
 Three hundred and five samples of normal thyroid tissue (30 samples), benign 
(41 samples of adenomatous goiter, 28 of follicular adenoma, 30 of thyroiditis, 27 of 
Graves disease and 25 of Hürtle adenoma) and malignant (45 samples of papillary 
carcinoma, 40 of follicular carcinoma, 28 of medullar carcinoma and 11 of anaplastic 
carcinoma) thyroid lesions were examined for the presence of FHIT protein (Table 1). 
The observed staining pattern was essentially identical in all positive lesions and was 
represented by the weak to strong cytoplasmic staining of normal or tumor cells 
(Figure 1A, 1B, 1C and 1D). 
 Of 30 normal thyroid tissue that were examined 29 (96%) were positive for 
FHIT protein and the majority of samples 23 (76%) showed a moderate expression of 
FHIT protein. Only 6 (20%) samples of normal thyroid tissue showed a strong 
expression of FHIT protein  (Figure 1A) and one sample was negative. 
FHIT protein expression was more frequent in benignant than in malignant 
thyroid lesions. Of 151 benign thyroid lesions that were examined, 142 (94 %) were 
positive for FHIT protein and 66 (44 %) showed a moderate expression of FHIT 
protein (Figure 1B). The majority of adenomatous goiter (41%), follicular adenoma 
(53%), Graves disease (48%) and Hürtle adenoma (44%) samples showed a moderate 
FHIT protein expression. Only in thyroiditis majority of samples (64%) showed 
strong immunohistochemical staining of FHIT protein (Table 1).  
On the contrary, the most malignant thyroid lesions were negative for FHIT 
protein, 59 (48 %) of 124 examined. The majority of follicular carcinoma (50%), 
medullary carcinoma (68%), anaplastic carcinoma (73%) samples showed a negative 
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FHIT protein expression. Only in papillary carcinoma majority of samples (44%) 
showed strong immunohistochemical staining of FHIT protein (Table 1)(Figure 1C 
and 1D).  
 
Loss of heterozygosity  
One hundred sixty and five samples of benign (30 samples of adenomatous 
goiter, 20 of follicular adenoma, 20 of thyroiditis, 22 of Graves disease and 19 of 
Hürtle adenoma) and malignant (11 samples of papillary carcinoma, 17 of follicular 
carcinoma, 15 of medullary carcinoma and 11 of anaplastic carcinoma) thyroid 
lesions were examined for the loss of heterozygosity (LOH) at the FHIT and p53 
genes loci (Table 2, 3 and 4). 
To analyze LOH at the FHIT gene we used two microsatellite markers within 
the FHIT gene, D3S1300 dinucleotide repeat and D3S4103 trinucleotide repeat. 
Normal DNA showed one (homozygous, not informative patients) or two 
(heterozygous, informative patients) bands at both microsatellite markers. Allelic 
deletion of FHIT was judged by a positive LOH at any of the two sites. The LOH of 
FHIT gene was more frequent in malignant than in benignant thyroid lesions. Of 111 
benignant thyroid lesions analyzed, 103 (92.8%) were heterozygous for analyzed loci 
and only 4 (3.9%) demonstrated LOH of the FHIT gene (2 adenomatous goiter, 1 
follicular adenoma and 1 Hürtle adenoma) (Table 2). Of 54 malignant thyroid tumors 
analyzed, 50 (92.6%) were heterozygous and 28 (56%) demonstrated LOH of the 
FHIT gene (Table 3 and 4). Figure 2. represents the example of FHIT gene LOH at 
D3S4103 locus.  
To analyze LOH at the p53 gene we used highly informative exogenic (CA)n 
repeat. The LOH of p53 gene was also more frequent in malignant than in benign 
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thyroid lesions. Of 111 benign thyroid lesions examined, 90 (81.1%) were 
heterozygous and only 1 Hürtle adenoma (1.1%) demonstrated LOH of the p53 gene 
(Table 2). Of 54 malignant thyroid tumors analyzed, 44 (81.5%) were heterozygous 
and 18 (40.9%) demonstrated LOH of the p53 gene (Table 3 and 4). 
LOH of the FHIT gene was more frequent event in malignant thyroid tumors 
than p53 gene LOH. 
 
FHIT gene expression  
 FHIT gene status was examined by RT-PCR analysis for the presence of 
aberrant FHIT transcripts (Tables 2-4). According to the results, tumor samples were 
divided into two categories: FHIT normal and FHIT aberrant (exon missing). The size 
of normal PCR product (normal FHIT gene status) was 814 bp, and the sizes of 
aberrant products were from 350-690 bp (Figure 3). 
 Of 111 benign thyroid lesions analyzed, in 4 (3.6 %) aberrant FHIT gene 
transcripts were found (Table 2). Of 54 malignant thyroid tumors analyzed, in 19 
(35.2 %) aberrant FHIT gene transcripts were found (3 papillary carcinoma, 1 
follicular carcinoma, 7 medullary carcinomas and 8 anaplastic carcinomas) (Table 3 
and 4). Anaplastic carcinomas displayed mutations in FHIT gene in almost all cases. 
Deletions were found in 5 cases and insertions in 3 cases of anaplastic carcinomas. In 
5 malignant tumors FHIT gene status was not analyzed (Table 4). 
 
FHIT gene expression and apoptosis  
 Results of FHIT gene expression in malignant thyroid tumors were correlated 
with the rate of apoptosis in the same tumors. The rate of apoptosis in tumors with 
normal FHIT transcript was between 35% and 68% (mean value 57.4%) and in 
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tumors with aberant transcripts was between 6% and 28% (mean value 16.7%). There 
was statistically significant lower rate of apoptosis in tumors with aberrant FHIT 
transcripts (p<0.01) (Figure 4).  
 
p53 gene mutation analysis 
 Results of p53 gene mutation analysis in benign lesions are summarized in 
Table 2. The majority of benignant thyroid lesions do not display mutation in p53 
gene. Only one follicular adenoma showed point mutation at codon 237 (ATG>ATT) 
resulting in Met>Ile amino acid change. 
Results of p53 gene mutations analysis in malignant thyroid tumors are 
summarized in Tables 3 and 4 and Figure 4. Gene p53 was mutated in one papillary 
carcinoma, single point mutation at codon 237 was present resulting in Met>Ile amino 
acid change, while second tumor showed LOH at p53 locus. Both tumors displayed 
concomitant mutation in FHIT gene and had distant metastases. Mutations in p53 
locus were much more frequent event in two malignant forms of thyroid neoplasms: 
medullary and anaplastic carcinomas. Eight out of 15 medullary carcinomas harbored 
single point mutation or LOH. In two tumors CGA>TGA point mutation at codon 213 
(Arg>Termination) was found and in one TGT>TAT mutation at codon 238 
(Cys>Tyr). 
 Anaplastic carcinomas displayed mutations in p53 gene in almost all cases. 
p53 gene was mutated in 7 tumors (LOH in 2 cases and point mutations in 5 cases) 
(Table 4). The point mutation GTA>GAA at p53 gene codon 193 (His>Leu) was 
found in one anaplastic carcinoma, but in extranodular metastasis of the same tumor 
another mutation, GGC>GGT at the p53 gene codon 248, was found (Figure 5). 
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Anaplastic tumors which harbored mutations in both genes displayed relative 
low percentage of apoptosis but not statistically significant (Figure 6). 
 
Tumorigenicity in nude mice 
Nude mice were inoculated with 2 x 107 cells of primary cultures of two 
folicular carcinoma. Morphological, genetical and immunohistochemical 
characteristics are shown in Table 5. The molecular genetic changes in p53-/FHIT- 
tumor were: LOH and point mutation of p53 gene at codon 234 (TAC>TGC resulting 
with aminoacid mutation Tyr>Cys), exon 5-8 missing together with LOH of FHIT 
gene and low rate of apoptosis (5%). In p53+/FHIT+ tumour p53 and FHIT genes 
were not mutated and apoptosis rate was much higher (39%). p53-/FHIT- tumors 
growth was much faster than p53+/FHIT+ tumors and this difference was statistically 
significant (p<0.01) (Figure 7) and mice survival rate was shorter.  
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Discussion 
Our results showed that FHIT gene is disrupted in thyroid lesions and hence, 
loss of FHIT protein function, together with aberration of p53 gene, increased tumor 
cell proliferation and low rate of apoptosis may be important in the development 
and/or progression of thyroid cancer. Recently we obtained similar results on head 
and neck sqamous cell carcinomas [15]. We also found higher incidence of p53 
mutation and aberrant processing of FHIT mRNA in more advanced undifferentiated 
tumors (in metastatic papillary and follicular, medullary and particularly in anaplastic 
carcinomas). 
The pattern of abnormal FHIT transcript in our present study as well as in Zou 
et al study [2] is similar to those reported in lung, breast and head and neck cancers 
[6,10,15,24]. The majority of aberrant FHIT trancripts lack exons 4-5, 5-7, 5-8 or 4-8. 
In addition we as well as Zou et al. described deletions (between exons 4 and 5) and 
insertions (replacing exons 5-8) [2]. Given that defective FHIT genes were found in 
both benign and malignant thyroid tumors, the innactivation of FHIT gene is likely to 
be an early event in the pathogenesis of some forms of thyroid neoplasms. 
 Truncated FHIT transcripts were observed frequently alongside full length 
transcripts. Sequence analysis of the truncated gene transcripts revealed mainly exon 
skipping and alternate RNA processing events. Generalized defect in transcription 
control and fidelity could have a significant effect on tumor progression, subtly 
altering transcription patterns of many genes simultaneously and potentially creating 
changes in cellular growth [17]. Our results strongly indicate that aberrant mRNA 
processing is more common in more advanced tumors, particularly in anaplastic 
carcinomas.  
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 Aberrant expression of FHIT gene is related to cell proliferation and apoptosis 
[15]. Overexpression of the FHIT gene induces cell apoptosis and alteres cell-cycle 
processes. The apoptotic cell population markedly increased, and cells accumulated in 
S-phase after FHIT transduction. Ji et al. [25] suggested that the FHIT gene, when 
delivered at high efficiency into HI2 199 lung cancer cells by a recombinant 
adenoviral vector, functions as a tumor suppressor gene both in vitro and in vivo.  
Sard et al. [23] transferred FHIT gene into lung cancer cell line H460 lacking FHIT 
protein expression. Gene transfer resulted in reversion of tumorigenicity. A significant 
inhibition of cell growth was observed in transfected cells, and again a high rate of 
apoptosis induced DNA strand breaks in stable clones. FACScan analysis showed an 
apoptotic rate of 44-47% compared with a 15% level in the control H460 cells. Our 
results support clinical relevance of transfection experiments. Observed growth 
inhibitory effect of FHIT re-expressing cells could be related to apoptosis and cell-
cycle arrest and link the tumor-suppressor activity of FHIT protein to its proapoptotic 
function. A role of FHIT protein as a proapoptotic factor is in agreement with the 
structural and biochemical studies indicating that FHIT-Ap3A complex is the native 
FHIT form involved in cellular signaling and apoptosis in human tumors to a decrease 
in Ap3A level [26,27]. 
In our study results of FHIT gene expression in malignant thyroid tumors were 
correlated with the rate of apoptosis in the same tumors. The rate of apoptosis in 
tumors with normal FHIT transcript was between 35% and 68% (mean value 57.4%) 
and in tumors with aberant transcripts was between 6% and 28% (mean value 16.7%). 
There was statistically significant lower rate of apoptosis in tumors with aberrant 
FHIT transcripts (p<0.01). 
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The inactivation of tumor suppressor genes is considered to be a critical event 
in the multi-step genetic process leading to the development of most cancers [28,29]. 
Loss of heterozygosity in FHIT locus is relatively frequent event in thyroid cancer as 
one of the mechanisms for inacivation in this gene. Several authors have investigated 
the incidence of LOH in thyroid neoplasms [30,31]. Zou found the highest incidence 
of LOH in follicular carcinomas, with chromosome 2p and 3p the most frequently 
affected sites. Fine mapping of 3p showed LOH clustered in the telomeric region 
(3p21-ter) as well as at D3S1300 (3p14.2) where FHIT was located [2,32]. LOH in 
3p.14.2 region is highly localized to the microsatellite marker D3S1300, which 
displayed LOH in 73% of informative cases, while neighbouring microsatellite 
markers (D3S1234, D3S1481, D3S1480) had much lower rates of LOH (14-44%). 
This suggests selective allelic deletion in the D3S1300 region [17]. 
LOH of FHIT gene has been associated with both benign and malignant 
thyroid lesions suggesting that FHIT aberration may be an early event in development 
of thyroid cancer [2,33], although some data do not support an association between 
FHIT loss and the stage, histological grade or outcome in human thyroid cancer. Our 
data suggest strong difference in the FHIT aberration between benign and malignant 
thyroid lesions. Benign lesions have much less incidence of FHIT loss in comparison 
to malignant. Follicular carcinomas in our study show relatively high incidence of 
LOH at FHIT loci. 
There is considerable controversy concerning when p53 mutations arise during 
thyroid tumor development [34-36]. The p53 gene has been implicated as a tumor 
suppressor gene whose inactivation by mutation has been noted in a variety of human 
malignancies. Cultured cells harboring p53 mutations are unable to grow when 
transplanted in vivo [37] suggesting that the timing of p53 mutation is a crucial step in 
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tumor progression. Some data have shown that p53 affects proliferative capabilities of 
thyroid cells in vitro [38]. Loss of p53 function could lead to genome destabilization 
promoting development of additional mutations [5]. Alternatively, p53 gene loss may 
lead to deregulation in apoptotic pathways, shifting the balance between the anti-
apoptotic and pro-apoptotic signals.  
Most data suggest that p53 mutations are involved in the transformation of 
thyroid cells and thyroid tumor progression [18,32,38-41]. Mutation of the p53 gene 
are associated with the most aggressive histologic types of thyroid tumors, such as 
undifferentiated carcinoma, and that the alterations of this gene represent a late 
genetic event in human thyroid carcinogenesis [32]. Our results as well as those of 
other authors show that p53 mutations are mainly present in poorly differentiated 
tumors and almost exclusively in those papillary and folicullar carcinomas with 
distant metastases. Inactivation of p53 may confer these neoplasms with aggressive 
properties, and further loss of differentiated functions. Fagin et al. [41] confirmed that 
in both anaplastic tumors and cell lines, examples of heterozygous and homozygous 
p53 mutations were identified. Transition observed in all positive anaplastic thyroid 
carcinoma samples involved CpG mutation. Because the cytosine in the CpG 
dinucleotide on codon 273 has been found to be methylated in vivo, the high mutation 
rate at this site in anaplastic carcinoma could be due to deamination of the methylated 
cytosine and replacement by a thymine. Mutations in different locations of p53 gene 
may have different biological consequences. Several mutations including that of 
codon 273, showed loss of transcriptional activity due to impairment of p53 binding 
to specific DNA recognition sequences [41,42]. Therefore this mutation may confere 
growth advantage to cells harboring mutations of oncogenes. 
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Both p53 and FHIT tumor suppressor gene mutations have been found 
frequently in undifferentiated thyroid carcinomas [2,43,44], but infrequently in 
differentiated thyroid cancers [45] and more commonly in anaplastic and poorly 
differentiated tumors [46]. Asakawa and Kobayashi [47] think that subsequent p53 
mutation may have caused the follicular neoplasm to transform to anaplastic 
carcinoma in some cases. Powell thinks that FHIT and p53 gene loss may occur prior 
to lose of differentiated structures in  advanced cancers. Thus as genes that control 
growth and apoptosis are mutated, the genotype of a given thyroid tumor may not 
reflect the observed phenotype, which may explain the missleading diagnosis 
associated with differentiated and poor thyroid outcome [48,49].  
The mechanisms responsible for the transformation of normal thyroid cells 
into carcinoma are not well understood. To define the role of RET, PTC3 and p53 
genes together with gene FHIT in thyroid cancerogenesis, Powell et al. [5] 
intercrossed RET/PTC3 transgenics with p53-/- mice. This new strain, RET/PTC3 p53-/-
succumb to rapidly growing and large multilobed thyroid tumors containing mixtures 
of both well and poorly differentiated, highly proliferative follicular epithelial cells. 
Similarly, expression of FHIT protein was reduced in early tumors and undetected in 
older tumors irrespective of tumor histopathology [5]. The analysis of thyroid tumors 
that develop in RET/PTC3 p53-/- or RET/PTC1+ p53-/-  mice [50] have revealed an 
important role of p53 gene loss in the progression of differentiated thyroid cancer into 
an advanced poorly differentiated malignancy. 
In our study, p53+/FHIT+ tumour p53 and FHIT genes were not mutated and 
apoptosis rate was much higher (39%). p53-/FHIT- tumors growth was much faster in 
nude mices than p53+/FHIT+ tumors and this difference was statistically significant 
(p<0.01) and mice survival rate was shorter.  
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In conclusion, our results show a correlation between aberrant FHIT and p53 
expression, low rate of apoptosis, and malignancy. Our results support the hypothesis 
that FHIT gene alteration is involved in development of thyroid gland lesions and that 
aberrant FHIT and p53 genes could be a prognostic marker in highly malignant 
thyroid lesions.  
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FIGURE LEGENDS 
 
FIGURE 1. Immunohistochemical analysis of FHIT protein. A. Normal thyroid 
tissue, strong immunostaining (3); B. Adenomatous goiter, moderate immunostaining 
(2); C. Papillary carcinoma, weak immunostaining (1); D. Anaplastic carcinoma, 
negative immunostaining (0). Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded tissue specimens (magnifications: A i B, 250X; C i D, 
1000X). 
 
FIGURE 2. Loss of heterozygosity (LOH) analysis of D3S4103 polymorphic marker 
in thyroid cancer. M, DNA marker pBR322/MspI; N, Normal tissue; T, Tumor tissue. 
1, heterozygous sample with LOH; 2, 3, heterozygous sample without LOH.  
 
FIGURE 3. Expression of the FHIT gene by nested RT-PCR. 
Normal FHIT products in three adenomatous goiters (lines A1, A2 and B2) and one 
follicular adenoma (line B1), 706 bp. Aberant FHIT products in two papillary 
carcinomas (lines A3 and A4), 360 bp, and two anaplastic carcinomas (lines B3 and 
B4), 620 bp. 
 
FIGURE 4. Correlation between FHIT gene status and percent of apoptosis in tumor 
cells. There was statistically significant lower rate of apoptosis in tumors with 
aberrant FHIT transcripts (p<0.01). 
 
FIGURE 5. Direct sequencing of PCR products containing a p53 gene mutations. A. 
The point mutation GTA>GAA at p53 gene codon 193 (His>Leu) was found in one 
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anaplastic carcinoma, but in B. extranodular metastasis of the same tumor another 
mutation, GGC>GGT at the p53 gene codon 248, was found. 
 
FIGURE 6. Percent of apoptosis in tumor cells in two groups of anaplastic 
carcinomas, p53 MUT / FHIT MUT and p53 WT / FHIT MUT. 
 
FIGURE 7. Tumorigenicity of follicular thyroid carcinoma cells from primary 
culture. The p53-/FHIT- cells or p53+/FHIT+ cells were injected s.c. into nude mice 
and tumor sizes and survival were measured. p53-/FHIT- tumors growth was much 
faster than p53+/FHIT+ tumors and this difference was  statistically significant 
(p<0.01). 
 
TABLE 1. Expression of FHIT protein in benign and malignant thyroid lesions 
 
 
 
 
FHIT protein status – expression (%) 
Thyroid lesion (No. analyzed) 
0 (negative) 1 (weak) 2 (moderate) 3 (strong) 
BENIGNANT THYROID LESIONS     
Adenomatous goiter (41) 3 (7) 8 (20) 17 (41) 13 (32) 
Follicular adenoma (28) 3 (11) 3 (11) 15 (53) 7 (25) 
Thyroiditis (30) 0 (0) 1 (3) 10 (33) 19 (64) 
Graves disease (27) 1 (4) 3 (11) 13 (48) 10 (37) 
Hürtle adenoma (25) 2 (8) 2 (8) 11 (44) 10 (40) 
MALIGNANT THYROID TUMORS     
Papillary carcinoma (45) 12 (27) 3 (7) 10 (22) 20 (44) 
Follicular carcinoma (40) 20 (50) 3 (8) 6 (15) 11 (27) 
Medullary carcinoma (28) 19 (68) 2 (7) 1 (4) 6 (21) 
Anaplastic carcinoma (11) 8 (73) 3 (27) 0 (0) 0 (0) 
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TABLE 2. Status of genes FHIT and p53 in benignant thyroid lesions 
 
 
 
FHIT gene status  p53 gene status BENIGNANT THYROID LESIONS 
(No. analyzed) N/EM/LOH WT/Point mutation/LOH 
Adenomatous goiter (30)   
27/30 (90%) N WT 
1/30 (3%) EM 8 WT 
2/30 (7%) LOH WT 
Follicular adenoma (20)   
18/20 (90%) N WT 
1/20 (5%) EM 5-7 ATG>ATT, Met> Ile (codon 237) 
1/20 (5%) LOH WT 
Thyroiditis (20)   
20/20 (100%) N WT 
Graves disease (22)   
21/22 (95%) N WT 
1/22 (5%) EM 8 WT 
Hürtle adenoma (19)   
17/19 (90%) N WT 
1/19 (5%) N LOH 
1/19 (5%) EM 5-7 + LOH WT 
 
 
N – Normal transcript; EM – exon missing; LOH – loss of heterozygosity; WT – wild type 
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TABLE 3. Status of genes FHIT and p53 in malignant thyroid tumors 
 
Thyroid tumor (No. analyzed) FHIT gene status  p53 gene status 
Patient No. TNM N/EM/LOH WT/Point mutation/LOH 
Papillary carcinoma (11)   
1 T4 N1a M0 LOH ND 
2 T2 N0 M0 LOH ND 
3 T1 N0 MO N WT 
4 T4 N0 M1 EM 8 ATG>ATT, Met>Ile (codon 237) 
5 T2 N0 M1 EM 5-7 + LOH LOH 
6 T1 N1a M0 EM 8 + LOH WT 
7 T2 N0 M0 N WT 
8 T2 N0 M0 LOH WT 
9 T2 N0 M0 LOH ND 
10 T2 N0 M1 LOH LOH 
11 T4 N1a M0 LOH LOH 
Follicular carcinoma (17)   
1 T3 N0 M1 LOH ND 
2 T2 N0 M0 LOH ND 
3 T2 N0 M0 EM 5-7 + LOH ND 
4 T3 N1 M0 N WT 
5 T2 N0 M1 N LOH 
6 T3 N0 M1 LOH LOH 
7 T2 N0 M0 LOH WT 
8 T2 N0 M0 N WT 
9 T3 N0 M1 LOH LOH 
10 T2 N0 M0 ND LOH 
11 T2 N0 M0 ND WT 
12 T2 N0 M0 LOH ND 
13 T2 N0 M1 N LOH 
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14 T3 N0 M1 N LOH 
15 T2 N0 M1 N LOH 
16 T2 N0 M0 LOH ND 
17 T2 N0 M0 LOH WT 
Medullary carcinoma (15)   
1 T2 N1a M0 LOH ND 
2 T2 N1a M0 LOH ND 
3 T3 N1a M1 N TGT>TAT, Cys>Tyr (codon 238) 
4 T2 N1a M1 EM 8 LOH 
5 T2 N0 M1 N CGA>TGA, Arg>Term (codon 213) 
6 T2 N1a M1 EM 4-8 LOH 
7 T3 N1a M0 EM 4-8 + LOH WT 
8 T3 N1a M0 72 bp insertion WT 
9 T2 N1a M0 EM 5-7 + LOH WT 
10 T3 N1a M1 N CGA>TGA, Arg>Term (codon 213) 
11 T2 N1a M0 LOH LOH 
12 T3 N1a M1 EM 8 LOH 
13 T2 N0 M1 EM 4-8 + LOH WT 
14 T3 N1a M0 N WT 
15 T2 N1a M1 N LOH 
 
N – Normal transcript; EM – exon missing; LOH – loss of heterozygosity; WT – wild type; ND – not 
determined 
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Table 4. Status of genes FHIT and p53, FHIT protein expression, apoptosis and survival in anaplasic carcinomas 
 
 
Patients FHIT gene status 
FHIT protein 
expresson 
p53 gene status Apoptosis Survival 
No. N/EM/LOH 0 (neg), 1 (weak) WT/Point mutation/LOH % months 
1 29 bp deletion + LOH 0 LOH 10 < 10 
2 839 bp deletion + LOH 0 LOH 16 < 10 
3 85 bp deletion 0 
1GTA>GAA, His>Leu (codon 193) 
2GGC>GGT (codon 248) 
7 6 
4 ND 1 CGT>CAT, Arg>His (codon 273) 4 10 
5 180 bp deletion 0 GGC>GGT (codon 248) ND 7 
6 ND 1 WT 28 12 
7 72 bp insertion + LOH 0 CGC>CCC, Arg>Pro (codon 238) 35 10 
8 180 bp deletion 0 WT 5 < 10 
9 9 bp insertion + LOH 1 WT 31 18 
10 839 bp insertion 0 CCT>TCT, Pro>Ger (codon 141) 22 12 
11 ND 0 WT 18 10 
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N – Normal transcript; EM – exon missing; LOH – loss of heterozygosity; WT – wild type; 1 primary anaplastic carcinoma; 2 extranodular metastasis 
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Table 5. Properties of two established thyroid cancer primary cell cultures 
 
 
 
Type of cell 
culture Morphology 
Doubling time 
(h) 
Immunohistochemistry 
marker (positive) Cytogenetics p53 FHIT Apoptosis (%) 
Growth in nude 
mice 
Follicular 
carcinoma 
polygonal flat-
to-spindle-like 
growing 
adherently as 
monolayer 
24 
cytokeratin 
neurofilament 
vimentin 
complex 
chromosomal 
changes 
Mutation at 
codon 234 
(TAC→TGC), 
LOH 
EM 5-8 
LOH 5 + fast 
Follicular 
carcinoma 
polygonal flat 
growing 
adherently as 
monolayer 
36 
cytokeratin 
vimentin 
desmin 
neurofilament 
near diploid 
karyotype with 
hexaploid 
sideline 
wilde type wilde type 39 + slow 
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Figure 1. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Expression of the FHIT gene by nested RT-PCR. 
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Figure 4. 
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Figure 5. 
 
 
 
 
A. Primary anaplastic carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Extranodular metastasis 
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Figure 6. 
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Figure 7. 
 
 
 
 
 
 
 
 
 
 
